Nanodrug Hijacking Blood Transferrin for Ferroptosis-Mediated Cancer Treatment
Journal of the American Chemical Society · 2024
DOI: 10.1021/jacs.4c00395 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Chemical Society, 2024. Verfasst von Shuyue Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Biomedical Engineering and National Engineering Research Center for Biomaterials, Sichuan University, 610064 Chengdu, China. Hauptthemen laut MEDLINE: Ferroptosis, Nanoparticles, Neoplasms. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Sichuan Science and Technology Innovation Foundation.
Abstract (Originalsprache)
Ferroptosis as a promising method of cancer treatment heavily relies on the intracellular iron ion level. Herein, a new iron-supplement nanodrug was developed by conjugating transferrin-homing peptide T10 on the surface of cross-linked lipoic acid vesicles (T10@cLAV), which could hijack blood transferrin (Tf) and specifically deliver it to tumor cells to elevate the Fe2+ level. Meanwhile, the intracellular degradation product of cLAV, dihydrolipoic acid, could regenerate Fe2+ to further boost the ferroptosis. The results disclosed that T10@cLAV achieved tumor inhibition comparable to that of cisplatin at a dose as low as 5 mg/kg in the HeLa tumor-bearing nude mice model and caused no toxicity at the dose up to 300 mg/kg. This tactful iron-supplement strategy of hijacking blood Tf is superior to the current strategies: one is the induction of intracellular ferritin degradation, which is limited by the low content of ferritin, and the other is the delivery of iron-based materials, which easily causes adverse effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- College of Biomedical Engineering and National Engineering Research Center for Biomaterials, Sichuan University, 610064 Chengdu, China.
ORCID-Profile: Shiyong Zhang
Förderung
- National Natural Science Foundation of China
- Sichuan Science and Technology Innovation Foundation
Zitieren
APA
Zhang, S., Wu, X., Liao, X., & Zhang, S. (2024). Nanodrug Hijacking Blood Transferrin for Ferroptosis-Mediated Cancer Treatment. Journal of the American Chemical Society. https://doi.org/10.1021/jacs.4c00395
Vancouver
Zhang S, Wu X, Liao X, Zhang S. Nanodrug Hijacking Blood Transferrin for Ferroptosis-Mediated Cancer Treatment. Journal of the American Chemical Society. 2024. doi:10.1021/jacs.4c00395
BibTeX
@article{Zhang2024,
author = {Zhang, Shuyue and Wu, Xiao and Liao, Xiaoming and Zhang, Shiyong},
title = {Nanodrug Hijacking Blood Transferrin for Ferroptosis-Mediated Cancer Treatment},
journal = {Journal of the American Chemical Society},
year = {2024},
doi = {10.1021/jacs.4c00395}
}
EUVIMED